Global Campylobacter Diagnostics Market
Global Campylobacter Diagnostics Market

Campylobacter Diagnostics Comprehensive Study by Type (Culture-based Diagnosis, Rapid Detection Tests (Immunological, Molecular, and Other )), End User (Hospitals, Private Laboratories, Independent Physician Chambers, Others) Players and Region - Global Market Outlook to 2025

Campylobacter Diagnostics Market Segmented into XX Submarkets. | Forecast Years: 2020- 2025  

Nov 2020 Edition 200 Pages 215 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
Global Campylobacter Diagnostics Market Overview:
Campylobacter infection is an abnormality observed in the digestive system caused by campylobacter bacteria. Major symptoms of campylobacter infection include diarrhea, blood and mucus in stool, malaise, severe abdominal pain, nausea, fever, vomiting, and headache. The most common sources of Campylobacter infection are unpasteurized milk, raw poultry, or uncooked vegetables. Campylobacter infection is diagnosed through laboratory tests of stool, body fluids, or tissue.

Growth Drivers
  • Rising Number of People Affected with Campylobacter Infection
  • Increasing Geriatric Population Globally

Market Trends
  • Growing Clinical Research Studies for Campylobacter Diagnosis

Roadblocks
  • Unfavorable Medical Reimbursements

Opportunities
  • Increasing Research and Development Activities Focused on Campylobacter
  • Rising Purchasing Power of Developing Countries

Challenges
  • Low Awareness about Campylobacter Infection Diagnosis


Competitive Landscape:
The companies are now exploring the market by adopting mergers & acquisitions, expansions, investments, new developments in existing products, and collaborations as their preferred strategies. The players are also exploring new geographies and industries through expansions and acquisitions so as to avail a competitive advantage through combined synergies.
Some of the key players profiled in the report are Becton, Dickinson and Company (United States), Meridian Bioscience, Inc. (United States), Thermo Fisher Scientific (United States), BIOTECON Diagnostics (Germany), Agilent Technologies (United States), Alere Inc. (United States), QIAGEN (Germany), Roche Molecular Systems, Inc. (United States), Siemens Healthineers (Germany), Lonza (Switzerland), ZeptoMetrix (United States) and Sequenom (United States). Analyst at AMA Research see United States Players to retain maximum share of Global Campylobacter Diagnostics market by 2025. Considering Market by End User, the sub-segment i.e. Hospitals will boost the Campylobacter Diagnostics market.

Available Customization:
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be provided prior to purchase

Research Methodology:
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Campylobacter Diagnostics market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Campylobacter Diagnostics market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes New Entrants/Investors, Analysts and Strategic Business Planners, Campylobacter Diagnostics Provider, Venture Capitalists and Private Equity Firms, Government Regulatory and Research Organizations and End-Use Industry.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.
Report Objectives / Segmentation Covered
By Type
  • Culture-based Diagnosis
  • Rapid Detection Tests (Immunological, Molecular, and Other )
By End User
  • Hospitals
  • Private Laboratories
  • Independent Physician Chambers
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rising Number of People Affected with Campylobacter Infection
      • 3.2.2. Increasing Geriatric Population Globally
    • 3.3. Market Challenges
      • 3.3.1. Low Awareness about Campylobacter Infection Diagnosis
    • 3.4. Market Trends
      • 3.4.1. Growing Clinical Research Studies for Campylobacter Diagnosis
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Campylobacter Diagnostics, by Type, End User and Region (value) (2014-2019)
    • 5.1. Introduction
    • 5.2. Global Campylobacter Diagnostics (Value)
      • 5.2.1. Global Campylobacter Diagnostics by: Type (Value)
        • 5.2.1.1. Culture-based Diagnosis
        • 5.2.1.2. Rapid Detection Tests (Immunological, Molecular, and Other )
      • 5.2.2. Global Campylobacter Diagnostics by: End User (Value)
        • 5.2.2.1. Hospitals
        • 5.2.2.2. Private Laboratories
        • 5.2.2.3. Independent Physician Chambers
        • 5.2.2.4. Others
      • 5.2.3. Global Campylobacter Diagnostics Region
        • 5.2.3.1. South America
          • 5.2.3.1.1. Brazil
          • 5.2.3.1.2. Argentina
          • 5.2.3.1.3. Rest of South America
        • 5.2.3.2. Asia Pacific
          • 5.2.3.2.1. China
          • 5.2.3.2.2. Japan
          • 5.2.3.2.3. India
          • 5.2.3.2.4. South Korea
          • 5.2.3.2.5. Taiwan
          • 5.2.3.2.6. Australia
          • 5.2.3.2.7. Rest of Asia-Pacific
        • 5.2.3.3. Europe
          • 5.2.3.3.1. Germany
          • 5.2.3.3.2. France
          • 5.2.3.3.3. Italy
          • 5.2.3.3.4. United Kingdom
          • 5.2.3.3.5. Netherlands
          • 5.2.3.3.6. Rest of Europe
        • 5.2.3.4. MEA
          • 5.2.3.4.1. Middle East
          • 5.2.3.4.2. Africa
        • 5.2.3.5. North America
          • 5.2.3.5.1. United States
          • 5.2.3.5.2. Canada
          • 5.2.3.5.3. Mexico
  • 6. Campylobacter Diagnostics: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2019)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Becton, Dickinson and Company (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Meridian Bioscience, Inc. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Thermo Fisher Scientific (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. BIOTECON Diagnostics (Germany)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Agilent Technologies (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Alere Inc. (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. QIAGEN (Germany)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Roche Molecular Systems, Inc. (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Siemens Healthineers (Germany)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Lonza (Switzerland)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. ZeptoMetrix (United States)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
      • 6.4.12. Sequenom (United States)
        • 6.4.12.1. Business Overview
        • 6.4.12.2. Products/Services Offerings
        • 6.4.12.3. Financial Analysis
        • 6.4.12.4. SWOT Analysis
  • 7. Global Campylobacter Diagnostics Sale, by Type, End User and Region (value) (2020-2025)
    • 7.1. Introduction
    • 7.2. Global Campylobacter Diagnostics (Value)
      • 7.2.1. Global Campylobacter Diagnostics by: Type (Value)
        • 7.2.1.1. Culture-based Diagnosis
        • 7.2.1.2. Rapid Detection Tests (Immunological, Molecular, and Other )
      • 7.2.2. Global Campylobacter Diagnostics by: End User (Value)
        • 7.2.2.1. Hospitals
        • 7.2.2.2. Private Laboratories
        • 7.2.2.3. Independent Physician Chambers
        • 7.2.2.4. Others
      • 7.2.3. Global Campylobacter Diagnostics Region
        • 7.2.3.1. South America
          • 7.2.3.1.1. Brazil
          • 7.2.3.1.2. Argentina
          • 7.2.3.1.3. Rest of South America
        • 7.2.3.2. Asia Pacific
          • 7.2.3.2.1. China
          • 7.2.3.2.2. Japan
          • 7.2.3.2.3. India
          • 7.2.3.2.4. South Korea
          • 7.2.3.2.5. Taiwan
          • 7.2.3.2.6. Australia
          • 7.2.3.2.7. Rest of Asia-Pacific
        • 7.2.3.3. Europe
          • 7.2.3.3.1. Germany
          • 7.2.3.3.2. France
          • 7.2.3.3.3. Italy
          • 7.2.3.3.4. United Kingdom
          • 7.2.3.3.5. Netherlands
          • 7.2.3.3.6. Rest of Europe
        • 7.2.3.4. MEA
          • 7.2.3.4.1. Middle East
          • 7.2.3.4.2. Africa
        • 7.2.3.5. North America
          • 7.2.3.5.1. United States
          • 7.2.3.5.2. Canada
          • 7.2.3.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Campylobacter Diagnostics: by Type(USD Million)
  • Table 2. Campylobacter Diagnostics Culture-based Diagnosis , by Region USD Million (2014-2019)
  • Table 3. Campylobacter Diagnostics Rapid Detection Tests (Immunological, Molecular, and Other ) , by Region USD Million (2014-2019)
  • Table 4. Campylobacter Diagnostics: by End User(USD Million)
  • Table 5. Campylobacter Diagnostics Hospitals , by Region USD Million (2014-2019)
  • Table 6. Campylobacter Diagnostics Private Laboratories , by Region USD Million (2014-2019)
  • Table 7. Campylobacter Diagnostics Independent Physician Chambers , by Region USD Million (2014-2019)
  • Table 8. Campylobacter Diagnostics Others , by Region USD Million (2014-2019)
  • Table 9. South America Campylobacter Diagnostics, by Country USD Million (2014-2019)
  • Table 10. South America Campylobacter Diagnostics, by Type USD Million (2014-2019)
  • Table 11. South America Campylobacter Diagnostics, by End User USD Million (2014-2019)
  • Table 12. Brazil Campylobacter Diagnostics, by Type USD Million (2014-2019)
  • Table 13. Brazil Campylobacter Diagnostics, by End User USD Million (2014-2019)
  • Table 14. Argentina Campylobacter Diagnostics, by Type USD Million (2014-2019)
  • Table 15. Argentina Campylobacter Diagnostics, by End User USD Million (2014-2019)
  • Table 16. Rest of South America Campylobacter Diagnostics, by Type USD Million (2014-2019)
  • Table 17. Rest of South America Campylobacter Diagnostics, by End User USD Million (2014-2019)
  • Table 18. Asia Pacific Campylobacter Diagnostics, by Country USD Million (2014-2019)
  • Table 19. Asia Pacific Campylobacter Diagnostics, by Type USD Million (2014-2019)
  • Table 20. Asia Pacific Campylobacter Diagnostics, by End User USD Million (2014-2019)
  • Table 21. China Campylobacter Diagnostics, by Type USD Million (2014-2019)
  • Table 22. China Campylobacter Diagnostics, by End User USD Million (2014-2019)
  • Table 23. Japan Campylobacter Diagnostics, by Type USD Million (2014-2019)
  • Table 24. Japan Campylobacter Diagnostics, by End User USD Million (2014-2019)
  • Table 25. India Campylobacter Diagnostics, by Type USD Million (2014-2019)
  • Table 26. India Campylobacter Diagnostics, by End User USD Million (2014-2019)
  • Table 27. South Korea Campylobacter Diagnostics, by Type USD Million (2014-2019)
  • Table 28. South Korea Campylobacter Diagnostics, by End User USD Million (2014-2019)
  • Table 29. Taiwan Campylobacter Diagnostics, by Type USD Million (2014-2019)
  • Table 30. Taiwan Campylobacter Diagnostics, by End User USD Million (2014-2019)
  • Table 31. Australia Campylobacter Diagnostics, by Type USD Million (2014-2019)
  • Table 32. Australia Campylobacter Diagnostics, by End User USD Million (2014-2019)
  • Table 33. Rest of Asia-Pacific Campylobacter Diagnostics, by Type USD Million (2014-2019)
  • Table 34. Rest of Asia-Pacific Campylobacter Diagnostics, by End User USD Million (2014-2019)
  • Table 35. Europe Campylobacter Diagnostics, by Country USD Million (2014-2019)
  • Table 36. Europe Campylobacter Diagnostics, by Type USD Million (2014-2019)
  • Table 37. Europe Campylobacter Diagnostics, by End User USD Million (2014-2019)
  • Table 38. Germany Campylobacter Diagnostics, by Type USD Million (2014-2019)
  • Table 39. Germany Campylobacter Diagnostics, by End User USD Million (2014-2019)
  • Table 40. France Campylobacter Diagnostics, by Type USD Million (2014-2019)
  • Table 41. France Campylobacter Diagnostics, by End User USD Million (2014-2019)
  • Table 42. Italy Campylobacter Diagnostics, by Type USD Million (2014-2019)
  • Table 43. Italy Campylobacter Diagnostics, by End User USD Million (2014-2019)
  • Table 44. United Kingdom Campylobacter Diagnostics, by Type USD Million (2014-2019)
  • Table 45. United Kingdom Campylobacter Diagnostics, by End User USD Million (2014-2019)
  • Table 46. Netherlands Campylobacter Diagnostics, by Type USD Million (2014-2019)
  • Table 47. Netherlands Campylobacter Diagnostics, by End User USD Million (2014-2019)
  • Table 48. Rest of Europe Campylobacter Diagnostics, by Type USD Million (2014-2019)
  • Table 49. Rest of Europe Campylobacter Diagnostics, by End User USD Million (2014-2019)
  • Table 50. MEA Campylobacter Diagnostics, by Country USD Million (2014-2019)
  • Table 51. MEA Campylobacter Diagnostics, by Type USD Million (2014-2019)
  • Table 52. MEA Campylobacter Diagnostics, by End User USD Million (2014-2019)
  • Table 53. Middle East Campylobacter Diagnostics, by Type USD Million (2014-2019)
  • Table 54. Middle East Campylobacter Diagnostics, by End User USD Million (2014-2019)
  • Table 55. Africa Campylobacter Diagnostics, by Type USD Million (2014-2019)
  • Table 56. Africa Campylobacter Diagnostics, by End User USD Million (2014-2019)
  • Table 57. North America Campylobacter Diagnostics, by Country USD Million (2014-2019)
  • Table 58. North America Campylobacter Diagnostics, by Type USD Million (2014-2019)
  • Table 59. North America Campylobacter Diagnostics, by End User USD Million (2014-2019)
  • Table 60. United States Campylobacter Diagnostics, by Type USD Million (2014-2019)
  • Table 61. United States Campylobacter Diagnostics, by End User USD Million (2014-2019)
  • Table 62. Canada Campylobacter Diagnostics, by Type USD Million (2014-2019)
  • Table 63. Canada Campylobacter Diagnostics, by End User USD Million (2014-2019)
  • Table 64. Mexico Campylobacter Diagnostics, by Type USD Million (2014-2019)
  • Table 65. Mexico Campylobacter Diagnostics, by End User USD Million (2014-2019)
  • Table 66. Company Basic Information, Sales Area and Its Competitors
  • Table 67. Company Basic Information, Sales Area and Its Competitors
  • Table 68. Company Basic Information, Sales Area and Its Competitors
  • Table 69. Company Basic Information, Sales Area and Its Competitors
  • Table 70. Company Basic Information, Sales Area and Its Competitors
  • Table 71. Company Basic Information, Sales Area and Its Competitors
  • Table 72. Company Basic Information, Sales Area and Its Competitors
  • Table 73. Company Basic Information, Sales Area and Its Competitors
  • Table 74. Company Basic Information, Sales Area and Its Competitors
  • Table 75. Company Basic Information, Sales Area and Its Competitors
  • Table 76. Company Basic Information, Sales Area and Its Competitors
  • Table 77. Company Basic Information, Sales Area and Its Competitors
  • Table 78. Campylobacter Diagnostics: by Type(USD Million)
  • Table 79. Campylobacter Diagnostics Culture-based Diagnosis , by Region USD Million (2020-2025)
  • Table 80. Campylobacter Diagnostics Rapid Detection Tests (Immunological, Molecular, and Other ) , by Region USD Million (2020-2025)
  • Table 81. Campylobacter Diagnostics: by End User(USD Million)
  • Table 82. Campylobacter Diagnostics Hospitals , by Region USD Million (2020-2025)
  • Table 83. Campylobacter Diagnostics Private Laboratories , by Region USD Million (2020-2025)
  • Table 84. Campylobacter Diagnostics Independent Physician Chambers , by Region USD Million (2020-2025)
  • Table 85. Campylobacter Diagnostics Others , by Region USD Million (2020-2025)
  • Table 86. South America Campylobacter Diagnostics, by Country USD Million (2020-2025)
  • Table 87. South America Campylobacter Diagnostics, by Type USD Million (2020-2025)
  • Table 88. South America Campylobacter Diagnostics, by End User USD Million (2020-2025)
  • Table 89. Brazil Campylobacter Diagnostics, by Type USD Million (2020-2025)
  • Table 90. Brazil Campylobacter Diagnostics, by End User USD Million (2020-2025)
  • Table 91. Argentina Campylobacter Diagnostics, by Type USD Million (2020-2025)
  • Table 92. Argentina Campylobacter Diagnostics, by End User USD Million (2020-2025)
  • Table 93. Rest of South America Campylobacter Diagnostics, by Type USD Million (2020-2025)
  • Table 94. Rest of South America Campylobacter Diagnostics, by End User USD Million (2020-2025)
  • Table 95. Asia Pacific Campylobacter Diagnostics, by Country USD Million (2020-2025)
  • Table 96. Asia Pacific Campylobacter Diagnostics, by Type USD Million (2020-2025)
  • Table 97. Asia Pacific Campylobacter Diagnostics, by End User USD Million (2020-2025)
  • Table 98. China Campylobacter Diagnostics, by Type USD Million (2020-2025)
  • Table 99. China Campylobacter Diagnostics, by End User USD Million (2020-2025)
  • Table 100. Japan Campylobacter Diagnostics, by Type USD Million (2020-2025)
  • Table 101. Japan Campylobacter Diagnostics, by End User USD Million (2020-2025)
  • Table 102. India Campylobacter Diagnostics, by Type USD Million (2020-2025)
  • Table 103. India Campylobacter Diagnostics, by End User USD Million (2020-2025)
  • Table 104. South Korea Campylobacter Diagnostics, by Type USD Million (2020-2025)
  • Table 105. South Korea Campylobacter Diagnostics, by End User USD Million (2020-2025)
  • Table 106. Taiwan Campylobacter Diagnostics, by Type USD Million (2020-2025)
  • Table 107. Taiwan Campylobacter Diagnostics, by End User USD Million (2020-2025)
  • Table 108. Australia Campylobacter Diagnostics, by Type USD Million (2020-2025)
  • Table 109. Australia Campylobacter Diagnostics, by End User USD Million (2020-2025)
  • Table 110. Rest of Asia-Pacific Campylobacter Diagnostics, by Type USD Million (2020-2025)
  • Table 111. Rest of Asia-Pacific Campylobacter Diagnostics, by End User USD Million (2020-2025)
  • Table 112. Europe Campylobacter Diagnostics, by Country USD Million (2020-2025)
  • Table 113. Europe Campylobacter Diagnostics, by Type USD Million (2020-2025)
  • Table 114. Europe Campylobacter Diagnostics, by End User USD Million (2020-2025)
  • Table 115. Germany Campylobacter Diagnostics, by Type USD Million (2020-2025)
  • Table 116. Germany Campylobacter Diagnostics, by End User USD Million (2020-2025)
  • Table 117. France Campylobacter Diagnostics, by Type USD Million (2020-2025)
  • Table 118. France Campylobacter Diagnostics, by End User USD Million (2020-2025)
  • Table 119. Italy Campylobacter Diagnostics, by Type USD Million (2020-2025)
  • Table 120. Italy Campylobacter Diagnostics, by End User USD Million (2020-2025)
  • Table 121. United Kingdom Campylobacter Diagnostics, by Type USD Million (2020-2025)
  • Table 122. United Kingdom Campylobacter Diagnostics, by End User USD Million (2020-2025)
  • Table 123. Netherlands Campylobacter Diagnostics, by Type USD Million (2020-2025)
  • Table 124. Netherlands Campylobacter Diagnostics, by End User USD Million (2020-2025)
  • Table 125. Rest of Europe Campylobacter Diagnostics, by Type USD Million (2020-2025)
  • Table 126. Rest of Europe Campylobacter Diagnostics, by End User USD Million (2020-2025)
  • Table 127. MEA Campylobacter Diagnostics, by Country USD Million (2020-2025)
  • Table 128. MEA Campylobacter Diagnostics, by Type USD Million (2020-2025)
  • Table 129. MEA Campylobacter Diagnostics, by End User USD Million (2020-2025)
  • Table 130. Middle East Campylobacter Diagnostics, by Type USD Million (2020-2025)
  • Table 131. Middle East Campylobacter Diagnostics, by End User USD Million (2020-2025)
  • Table 132. Africa Campylobacter Diagnostics, by Type USD Million (2020-2025)
  • Table 133. Africa Campylobacter Diagnostics, by End User USD Million (2020-2025)
  • Table 134. North America Campylobacter Diagnostics, by Country USD Million (2020-2025)
  • Table 135. North America Campylobacter Diagnostics, by Type USD Million (2020-2025)
  • Table 136. North America Campylobacter Diagnostics, by End User USD Million (2020-2025)
  • Table 137. United States Campylobacter Diagnostics, by Type USD Million (2020-2025)
  • Table 138. United States Campylobacter Diagnostics, by End User USD Million (2020-2025)
  • Table 139. Canada Campylobacter Diagnostics, by Type USD Million (2020-2025)
  • Table 140. Canada Campylobacter Diagnostics, by End User USD Million (2020-2025)
  • Table 141. Mexico Campylobacter Diagnostics, by Type USD Million (2020-2025)
  • Table 142. Mexico Campylobacter Diagnostics, by End User USD Million (2020-2025)
  • Table 143. Research Programs/Design for This Report
  • Table 144. Key Data Information from Secondary Sources
  • Table 145. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Campylobacter Diagnostics: by Type USD Million (2014-2019)
  • Figure 5. Global Campylobacter Diagnostics: by End User USD Million (2014-2019)
  • Figure 6. South America Campylobacter Diagnostics Share (%), by Country
  • Figure 7. Asia Pacific Campylobacter Diagnostics Share (%), by Country
  • Figure 8. Europe Campylobacter Diagnostics Share (%), by Country
  • Figure 9. MEA Campylobacter Diagnostics Share (%), by Country
  • Figure 10. North America Campylobacter Diagnostics Share (%), by Country
  • Figure 11. Global Campylobacter Diagnostics share by Players 2019 (%)
  • Figure 12. Global Campylobacter Diagnostics share by Players (Top 3) 2019(%)
  • Figure 13. Global Campylobacter Diagnostics share by Players (Top 5) 2019(%)
  • Figure 14. BCG Matrix for key Companies
  • Figure 15. Becton, Dickinson and Company (United States) Revenue, Net Income and Gross profit
  • Figure 16. Becton, Dickinson and Company (United States) Revenue: by Geography 2019
  • Figure 17. Meridian Bioscience, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 18. Meridian Bioscience, Inc. (United States) Revenue: by Geography 2019
  • Figure 19. Thermo Fisher Scientific (United States) Revenue, Net Income and Gross profit
  • Figure 20. Thermo Fisher Scientific (United States) Revenue: by Geography 2019
  • Figure 21. BIOTECON Diagnostics (Germany) Revenue, Net Income and Gross profit
  • Figure 22. BIOTECON Diagnostics (Germany) Revenue: by Geography 2019
  • Figure 23. Agilent Technologies (United States) Revenue, Net Income and Gross profit
  • Figure 24. Agilent Technologies (United States) Revenue: by Geography 2019
  • Figure 25. Alere Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 26. Alere Inc. (United States) Revenue: by Geography 2019
  • Figure 27. QIAGEN (Germany) Revenue, Net Income and Gross profit
  • Figure 28. QIAGEN (Germany) Revenue: by Geography 2019
  • Figure 29. Roche Molecular Systems, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 30. Roche Molecular Systems, Inc. (United States) Revenue: by Geography 2019
  • Figure 31. Siemens Healthineers (Germany) Revenue, Net Income and Gross profit
  • Figure 32. Siemens Healthineers (Germany) Revenue: by Geography 2019
  • Figure 33. Lonza (Switzerland) Revenue, Net Income and Gross profit
  • Figure 34. Lonza (Switzerland) Revenue: by Geography 2019
  • Figure 35. ZeptoMetrix (United States) Revenue, Net Income and Gross profit
  • Figure 36. ZeptoMetrix (United States) Revenue: by Geography 2019
  • Figure 37. Sequenom (United States) Revenue, Net Income and Gross profit
  • Figure 38. Sequenom (United States) Revenue: by Geography 2019
  • Figure 39. Global Campylobacter Diagnostics: by Type USD Million (2020-2025)
  • Figure 40. Global Campylobacter Diagnostics: by End User USD Million (2020-2025)
  • Figure 41. South America Campylobacter Diagnostics Share (%), by Country
  • Figure 42. Asia Pacific Campylobacter Diagnostics Share (%), by Country
  • Figure 43. Europe Campylobacter Diagnostics Share (%), by Country
  • Figure 44. MEA Campylobacter Diagnostics Share (%), by Country
  • Figure 45. North America Campylobacter Diagnostics Share (%), by Country
Some of the key companies/manufacturers profiled in the report
  • Becton, Dickinson and Company (United States)
  • Meridian Bioscience, Inc. (United States)
  • Thermo Fisher Scientific (United States)
  • BIOTECON Diagnostics (Germany)
  • Agilent Technologies (United States)
  • Alere Inc. (United States)
  • QIAGEN (Germany)
  • Roche Molecular Systems, Inc. (United States)
  • Siemens Healthineers (Germany)
  • Lonza (Switzerland)
  • ZeptoMetrix (United States)
  • Sequenom (United States)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation